Form 4: Trevi Therapeutics Executive Granted Stock Options

Farrell Simon, Chief Commercial Officer of Trevi Therapeutics, was granted stock options for 225,500 shares on February 18, 2025.

Summary

• This document is a Form 4 filing with the SEC, reporting a change in beneficial ownership for Simon Farrell, Chief Commercial Officer of Trevi Therapeutics, Inc.
• On February 18, 2025, Farrell was granted stock options to purchase 225,500 shares of Trevi Therapeutics common stock at an exercise price of $4.22 per share.
• The options vest as to 25% on February 18, 2026, and the remaining 75% vest in equal monthly installments through February 18, 2029.
• Following the transaction, Farrell directly owns options for 225,500 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the executive's role and the company's future.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

This document does not contain any specific forward-looking statements or guidance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The size of the grant and the vesting schedule are generally determined based on factors such as the executive's role, performance, and industry benchmarks.
• Comparable companies in the pharmaceutical industry, such as Galera Therapeutics or Cara Therapeutics, also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning executive interests with company performance.
• Employees may see this as a positive sign of investment in leadership.

Key Dates

Keywords

Trevi Therapeutics, Stock Options, Form 4, Beneficial Ownership, Executive Compensation, Simon Farrell, TRVI